Zobrazeno 1 - 10
of 113
pro vyhledávání: '"Smita, Kayal"'
Publikováno v:
JCO Global Oncology, Vol , Iss 10 (2024)
Gender disparities in young-onset CRC highlight health care access barriers in LMICs & changing global incidence trends. Increased awareness is crucial. #JCOGO @JCOGO_ASCO.
Externí odkaz:
https://doaj.org/article/0611bf7ba4e6467f92a11b6afa9ef573
Autor:
Soumya Surath Panda, Swati Sucharita Mohanty, Antara Sanyal, Prasanth Ganesan, Smita Kayal, Krishnakumar Rathnam, S. V. Saju, Sunu Cyriac, P. Unnikrishnan, Amit Sehrawat, Deepak Sundriyal, Ashwin Oommen Philips, Deepak Jain, Sumit Subhadarshi Mohanty, Sunil Kumar Agrawal, Lalatendu Moharana, Satyaprakash Ray Choudhury, Biswajit Dubashi
Publikováno v:
South Asian Journal of Cancer, Vol 13, Iss 02, Pp 142-145 (2024)
Externí odkaz:
https://doaj.org/article/0d12ee6a719a4c9d8766b0aa8b692ad5
Autor:
Amit Sehrawat, Mridul Khanna, Smita Kayal, Deepak Sundriyal, Shraddha Tiwari, Sunu Cyriac, Praveen Ravishankaran, Jomon Raphael, Dominic Mathew, Soumya Surath Panda, Laltendu Moharana, Sumit Subhadarshi Mohanty, Swati Sucharita Mohanty, Ashwin Philips, Deepak Jain, Pamela Jeyaraj, Parvez Haque David, Jaineet Patil, S.V. Saju, Krishnakumar Rathnam, Neha Sharma, Kaaviya Dheva, Sree Rekha Jinkala, Kalyarasaran Raja, Prasanth Penumadu, Prasanth Ganesan
Publikováno v:
JCO Global Oncology, Vol , Iss 10 (2024)
PURPOSEColorectal cancer (CRC) in young adults is a rising concern in developing countries such as India. This study investigates clinicopathologic profiles, treatment patterns, and outcomes of CRC in young adults, focusing on adolescent and young ad
Externí odkaz:
https://doaj.org/article/2c1dec7df5eb440fab598bffa591cd27
Autor:
Chitradurga Rajashekhar Akshatha, Dhanapathi Halanaik, Rajesh Nachiappa Ganesh, Nanda Kishore, Prasanth Ganesan, Smita Kayal, Harichandra Kumar, Biswajit Dubashi
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Triple-negative breast cancer (TNBC) includes approximately 20% of all breast cancer and is characterized by its aggressive nature, high recurrence rates, and visceral metastasis. Pathological complete response (pCR) is an established sur
Externí odkaz:
https://doaj.org/article/b6da289be2cc4ded8ba18010abbe56ac
Autor:
Narendran Krishnamoorthi, Lourdhusamy Charles, Yadav Nisha, Biswajit Dubashi, Prasanth Ganesan, Smita Kayal, Prasanth Penumadu, Vishnu Prasad Nelamangala Ramakrishnaiah, Rajesh Nachiappa Ganesh
Publikováno v:
South Asian Journal of Cancer, Vol 12, Iss 04, Pp 326-333 (2023)
Externí odkaz:
https://doaj.org/article/b11a6dc66cd44cf08992036763b2454b
Autor:
Fen Saj, Yadav Nisha, Prasanth Ganesan, Smita Kayal, Rakhee Kar, Dhanapathi Halanaik, Biswajit Dubashi
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-6 (2023)
Abstract Bortezomib, lenalidomide, and dexamethasone induction chemotherapy (VRd), followed by autologous stem cell transplantation (ASCT), are the standard of care for patients with newly diagnosed multiple myeloma (NDMM). Pomalidomide is currently
Externí odkaz:
https://doaj.org/article/247ba0f75d0747059a6addcd4a179b44
Autor:
Fen Saj, Yadav Nisha, Prasanth Ganesan, Smita Kayal, Rakhee Kar, Dhanapathi Halanaik, Biswajit Dubashi
Publikováno v:
HemaSphere, Vol 7, p e5135960 (2023)
Externí odkaz:
https://doaj.org/article/61213282c3384a2194f1f2b3567b074f
Autor:
Venkatraman Radhakrishnan, Sameer Bakhshi, Smita Kayal, Cherian Thampy, Ankit Batra, Praveen Kumar Shenoy, Hemanth Kumar, Swaminathan Rajaraman, Shilpi Chaudhary, Reema Bisht, Biswajit Dubashi, Trivadi S. Ganesan
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 9, Pp 1-10 (2022)
Abstract The benefit of three-drug induction chemotherapy over a two-drug induction has not been evaluated in pediatric acute myeloid leukemia (AML). We, therefore, conducted a randomized controlled trial to ascertain the benefit of a three-drug indu
Externí odkaz:
https://doaj.org/article/06a7de0642e74c8092c44bd295d75677
Autor:
Soumya Das, Smita Kayal, Biswajit Dubashi, Abhishekh Basavarajegowda, Nanda Kishore Pasupala, Rajendra Kulkarni, Krishnappa Dhanraju, Chinmaya Kumar Pani
Publikováno v:
Asian Journal of Transfusion Science, Vol 16, Iss 1, Pp 7-14 (2022)
BACKGROUND: Plerixafor is used for patients at risk of Stem cell mobilization failure based on clinical factors or low peripheral blood CD34 count. It is also added upfront to any mobilization irrespective of risk factor, but the cost-effectiveness o
Externí odkaz:
https://doaj.org/article/bb62a78020bb4d918d85e754849ecee8
Autor:
Arihant Jain, Lingaraj Nayak, Uday Prakash Kulkarni, Nikita Mehra, Uday Yanamandra, Smita Kayal, Sharat Damodar, Joseph M. John, Prashant Mehta, Suvir Singh, Pritesh Munot, Sushil Selvarajan, Venkatraman Radhakrishnan, Deepesh Lad, Rajan Kapoor, Biswajit Dubashi, Ram S. Bharath, Hasmukh Jain, P. K. Jayachandran, Jeyaseelan Lakshmanan, Thenmozhi Mani, Jayashree Thorat, Satyaranjan Das, Omprakash Karunamurthy, Biju George, Manju Sengar, Pankaj Malhotra
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 1, Pp 1-5 (2022)
Externí odkaz:
https://doaj.org/article/d76cc7db04ff43e4aed62e7c0c52626a